Zimmer Biomet Q1 rev +1.1%; guides 2025 adj EPS down to $7.90-$8.10, rev up including Paragon 28

ZIMMER BIOMET HOLDINGS, INC.

2025-Q1 EPS reported $0.91 revenue$1,909,100,000

Q1 net sales $1.909B (+1.1% reported, +2.3% CC); GAAP EPS $0.91, adjusted EPS $1.81.
2025 adjusted EPS guidance lowered to $7.90-$8.10 from $8.15-$8.35 due to Paragon 28, currency, and tariffs.
2025 reported revenue guidance raised to 5.7%-8.2% (includes Paragon 28); organic CC unchanged at 3%-5%.
Completed acquisition of Paragon 28 (foot and ankle orthopedics) in Q1 2025.
Chairman Begley retiring at May 29 meeting; CEO Tornos to become Chairman, Farrell Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.